A 400 - Sichuan Kelun-Biotech Biopharmaceutical
Alternative Names: A-400-Sichuan Kelun-Biotech Pharmaceutical; A400 - Sichuan Kelun-Biotech Biopharmaceutical; EP-0031; KL-590586Latest Information Update: 14 Jul 2024
At a glance
- Originator Sichuan Kelun-Biotech Biopharmaceutical
- Developer Ellipses Pharma; Sichuan Kelun-Biotech Biopharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Preclinical Brain metastases
Most Recent Events
- 31 May 2024 Updated efficacy, pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 May 2024 US FDA successfully completes phase I data review of phase I/II for A 400 in Solid tumors
- 05 Mar 2024 Ellipses Pharma anticipates to submit a New Drug Application (NDA) for A 400